A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).

Brian Hemendra Ramnaraign,Steven J. Hughes,Kathryn E. Hitchcock,Ji-Hyun Lee,Sherise C. Rogers,Z. Hugh Fan,Carmen J. Allegra,Jose G. Trevino,Ahmad El-Far,Karen Bullock Russell,Anita Ahmed Turk,David DeRemer,Thomas J. George

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).

2021

Brian Hemendra Ramnaraign
Steven J. Hughes
Kathryn E. Hitchcock
Ji-Hyun Lee
Sherise C. Rogers
Z. Hugh Fan
Carmen J. Allegra
Jose G. Trevino
Ahmad El-Far
Karen Bullock Russell
Anita Ahmed Turk
David DeRemer
Thomas J. George

TPS446Background: Neoadjuvant treatment for potentially curable pancreatic cancer (PDAC) is increasing in acceptability, but a standard regimen has yet to be established. Multiple studies have demo...

Keywords:

Oncology
neoadjuvant treatment
Internal medicine
Liposomal Irinotecan
Pancreatic cancer
open label
Adenocarcinoma
Regimen
preoperative treatment
Oxaliplatin
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations